I totally agree. I have been making this point for a long time. It is taking a long time for ZIOP to move this forward. IL-12 didn't work as well as they wanted as a mono therapy for breast and Melanoma but the company has refined the process a lot and with a PD1 you would assume things will be much more efficacious.
The synergy of the 2 should make PD1s much more effective. The company has been waiting for more data prior to making a deal to partner IL-12. They hinted today that they are seeing positive data and feel like IL-12 is a platform. We will get our first glimpse into the combo data this weekend. If you look at the pipeline they have a new indication ready to announce at any time. I would anticipate this will be announced as soon as they get a little additional GBM data.
The discussion on IL-12 was much more extensive than prior presentations. I got the sense that Dr. Cooper feels very confident in IL-12 moving forward.